Recepta biopharma

biotechnology in cancer treatment

port eng

News

June 2008

Recepta is included in Nature’s June 2008 comprehensive report on the biotechnology sector in Brazil.
Full story

Recepta’s CEO is a speaker at DIA’s 44th Annual Meeting in Boston.
Full story

February 2008

Recepta’s First Phase II clinical trial has been listed in the US at the NCI website.
Full story

November 2007

Innovating innovation
Partnership with Finep, Instituto Ludwig and Recepta Biopharma in the Monoclonal Antibodies Laboratory leads BI to take part of an unheard of initiative in Brazil
Full story

The win-win network
José Fernandes Perez, Recepta Biopharma president, explains to the Butantan Magazine the success of the network he set up to produce monoclonal antibodies in Brazil, enterprise in which BI plays an important role and which may be considered an innovation inside the innovation.
Full story

October 30, 2007

DSM Biologics and Crucell Announce PER.C6® Technology Licensing Deal
with Recepta biopharma

DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6®
technology research licensing agreement with Brazilian-based Recepta biopharma S.A.

Full story

June 14, 2007

RECEPTA biopharma will develop new therapies for cancer treatment
The Brazilian biotechnology company RECEPTA biopharma established by way of a partnership with the Ludwig Institute for Cancer Research, is setting up a network involving research institutions including the Butantan Institute
Full story